Logo

AbbVie Reports Results of Four-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia

Share this

AbbVie Reports Results of Four-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia

Shots:

  • The P-III CLL14 trial assessing the efficacy & safety of a combined regimen of Venclyxto/Venclexta + obinutuzumab vs obinutuzumab and chlorambucil in 432 patients with previously untreated CLL
  • Results: @median follow-up of 52.4 mos.- PFS rate (74% vs 35.4%) after 1 yr. fixed-duration treatment- 67% reduction in risk of disease progression or death; OS rate (85.4% vs 83.1%)- no new safety signals were identified- improvement in PFS was observed in all clinical & biological risk groups- includes TP53 mutation- 17p deletion & unmutated IGHV status
  • Additionally- 26.9% of patients with Venclyxto/Venclexta-based combination still had undetectable MRD compared to 3.2% of patients with obinutuzumab + chlorambucil arm @ 30 mos.

| Ref: Abbvie | Image:abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions